SB 239063An inhibitor of p38 MAP kinase

SB 239063 (CAS 193551-21-2)

SB 239063 | CAS 193551-21-2 is rated 5.0 out of 5 by 1.
  • y_2019, m_9, d_16, h_16
  • bvseo_bulk, prod_bvrr, vn_bulk_2.0.13
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_220094, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getAggregateRating, 77ms
  • REVIEWS, PRODUCT
Synonym: trans-1-(4-Hydroxycyclohexyl)-4-(4-fluorophenyl)-5-(2-methoxypyridimidin-4-yl)imidazole; trans-4-[4-(4-Fluorophenyl)-5-(2-methoxy-4-pyrimidinyl)-1H-imidazol-1-yl]cyclohexanol
Application: An inhibitor of p38 MAP kinase
CAS Number: 193551-21-2
Purity: ≥97%
Molecular Weight: 368.41
Molecular Formula: C20H21FN4O2
* Refer to Certificate of Analysis for lot specific data (including water content).
submit a review for this product and receive 15 cruzcredits

SB 239063 is a potent and selective p38 MAP kinase inhibitor. This chemical displays greater than 220-fold selectivity over ERK, JNK1 and other kinases, is approximately 3-fold more selective than SB 203580, and is selective for p38 α and p38 β with no activity against γ and δ isoforms. SB 239063 has been shown to decrease the number of activated microglia and facilitates neurogenesis. It also reduces inflammatory cytokine production and is neuroprotective.


References

1. Stinson, L.F. et al. 2014. Reproduction. 147(3): 313-320. PMID: 24493151

Physical State :
Solid
Solubility :
Soluble in 11 mg/ml DMSO
Storage :
Store at -20° C
Melting Point :
206-207.2° C
Boiling Point :
~594.76° C at 760 mmHg (Predicted)
Density :
~1.4 g/cm3 (Predicted)
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
WGK Germany :
3
PubChem CID :
5166
SMILES :
COC1=NC=CC(=N1)C2=C(N=CN2C3CCC(CC3)O)C4=CC=C(C=C4)F

Download SDS (MSDS)

Certificate of Analysis

Adobe Acrobat Reader is required to reliably view,
print and comment on PDF documents

SB 239063  Product Citations

See how others have used SB 239063. Click on the entry to view the PubMed entry .

Citations 1 to 1 of 1 total

PMID: # 21782178  Yonekawa, K. et al. 2011. Atherosclerosis. 218: 486-92.

Citations 1 to 1 of 1 total
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getContent, 65ms
  • QUESTIONS, PRODUCT
  • bvseo-msg: The resource to the URL or file is currently unavailable.;
Rated 5 out of 5 by from Stinson et al Stinson et al. (PubMed ID 24493151) found that SB239063 prevented accumulation of cytokines and PGE2 in the fetal and maternal compartment and also suppressed oIL8 production in pregnant patients who received intra-amniotically delivered CSAIDs for the prevention of inflammation-mediated preterm births.
Date published: 2015-06-27
  • y_2019, m_9, d_16, h_16
  • bvseo_bulk, prod_bvrr, vn_bulk_2.0.13
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_220094, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getReviews, 36ms
  • REVIEWS, PRODUCT

Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2019 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.